Active	Status	Sponsor type	Region	Phase	Filter
7 Active 0 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Jones, Nancy
FLAMINGO-01, NCT05232916: Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects	Recruiting	3	750	Europe, US	Placebo, GLSI-100	Greenwich LifeSciences, Inc.	Breast Cancer	12/26	12/26
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer	Recruiting	3	418	Europe, Canada, US, RoW	Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab	AbbVie, GOG Foundation	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	03/27	04/29
SGN35-015, NCT01716806 / 2019-003982-17: A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014) Nov 2014 - Nov 2014: Additional data for front-line Hodgkin's lymphoma in elderly patients (ASH 2014) For newly diagnosed Hodgkin's lymphoma in elderly patients Dec 2013 - Dec 2013: For newly diagnosed Hodgkin's lymphoma in elderly patients Elderly chemo-intolerant Hodgkin's lymphoma patients Nov 2013 - Nov 2013: Elderly chemo-intolerant Hodgkin's lymphoma patients Presentation of data from front line Hodgkin's lymphoma in elderly patients at ASH 2013 Nov 2013 - Nov 2013: Presentation of data from front line Hodgkin's lymphoma in elderly patients at ASH 2013 ASH 2013 Nov 2013 - Nov 2013: ASH 2013 More	Completed	2	131	Canada, US	brentuximab vedotin, Adcetris; SGN-35, bendamustine, dacarbazine, nivolumab	Seagen Inc., Bristol-Myers Squibb	Hodgkin Disease, Peripheral T Cell Lymphoma	04/23	09/23
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer	Completed	2	79	Europe, Canada, US, RoW	Mirvetuximab soravtansine, MIRV, IMGN853	AbbVie	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	01/24	12/24
KICKSTART, NCT04622007: Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC Jan 2024 - Mar 2024 : Q1'24 - Data from P2b KICKSTARTtrial in combination with Keytruda for PD-L1+ve 1L NSCLC	Active, not recruiting	2	68	US, RoW	Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta®	Effector Therapeutics, Medpace, Inc., ICON plc	Non-small Cell Lung Cancer	10/24	12/24
ACR-368-201, NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma	Recruiting	1/2	390	US	ACR-368, prexasertib, Gemcitabine, OncoSignature	Acrivon Therapeutics, GOG Foundation	Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma	07/26	12/27
BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry	Active, not recruiting	N/A	3465	US	Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test	Biotheranostics, Inc.	Breast Cancer	12/28	12/28